anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a percutaneous adsorption-type preparation of tulobuterol, having excellent skin permeability and reduced skin irritation, being easily produced, and having excellent drug stability.  <P>SOLUTION: The percutaneous adsorption-type preparation of tulobuterol has a supporter and an adhesive layer. The adhesive layer contains a styrene-isoprene-styrene copolymer (SIS) as an adhesive base material, and the tulobuterol of <5% concentration in a dissolved state. The adhesive layer further contains an acrylic adhesive comprising a polyisobutylene or an acrylic macromolecular material substantially containing no carboxy group and no hydroxy group in the molecule, and having adhesiveness at normal temperature as the adhesive base material. A silicone can be contained instead of the SIS as the adhesive base material.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The present invention relates to a disposable tissue for skin cleaning and UV protection and a method for manufacturing the same. The disposable tissue according to the present invention is characterized in that a tissue is impregnated with a composition including a Pueraria lobata var. thomsonii extract, a Lactuca indica extract, a turmeric extract, an aloe vera extract, a Centella asiatica extract, a Portulaca oleracea extract, menthol, and natural oil, has a skin cleaning effect that can maintain cleanliness by wiping away waste or adsorbed foreign substances on the skin of the human body and a UV protection effect, and can be usable even for sensitive skin without skin irritation or side effects. In addition, the disposable tissue having skin cleaning and UV protection effects is discarded after a single usage. Accordingly the disposable tissue is easy to carry and use for outdoor use. In addition, the disposable tissue has excellent antibacterial properties and thus can be used hygienically, thereby exhibiting high skin stability.
PURPOSE: The relationship between the number of chronic diseases and oral health problems is unclear. We sought to determine whether the number of chronic diseases and multimorbidity have an association with oral health problems in Korean adults.
MATERIALS AND METHODS: Data from 23,246 adults aged ≥ 19 years, who participated in the Korea National Health and Nutrition Examination Survey from 2016 to 2019, were considered for our analyses. Participants with either masticatory or speech problems were defined as the oral health problems group. Individuals who reported having had dental treatment in the last year were defined as the dental treatment group. We used multivariable logistic regression analyses to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
RESULTS: The proportions of oral health problems and dental treatment were higher in participants with multimorbidity than in those without multimorbidity (all p < 0.001). Moreover, ORs of oral health problems demonstrated a tendency to increase with the number of chronic diseases, even after adjustment (p for trend < 0.001). Compared to the participants without multimorbidity, the risk of having oral health problems increased by 25% (OR: 1.25, 95% CI: 1.12-1.39), and that of receiving dental treatment increased by 23% (OR: 1.23, 95% CI: 1.13-1.34) in patients with multimorbidity.
CONCLUSION: The risk of oral health problems and dental treatment increased in association with the number of chronic diseases in Korean adults. The authors emphasise the risks and importance of oral health in a large population affected by multiple chronic diseases.
Inflamed adipose tissue may contribute to blunted exercise response in skeletal muscle of older adults. The objective of this project is to evaluate a hypothesis that inflamed adipose secretes factors that activate inflammatory cascades in skeletal muscle, which may interfere with exercise-responsive molecular pathways and contribute to dysfunctional muscle phenotypes with aging. This project determine how adipose tissue influences skeletal muscle function and anabolic response to exercise in older adults. Young and older adults will complete studies to assess molecular response to acute exercise from protein synthesis rates, mRNA of exercise-responsive genes, and activation of signaling proteins in skeletal muscle. Adipose tissue will be assessed using a combination of non-invasive imaging and biopsy-based molecular phenotyping. The project will determine if acute exercise response is attenuated in older adults with inflamed adipose tissue phenotype.
A medication reminder and compliance system including a pill box, a pill box and electronic device; or a pill box, electronic device and remote server. The pill box includes several detachable dosettes, each divided into several chambers having a door. A two-color LED is disposed beneath each chamber and is activated when a specific reminder time is reached. The LED initially illuminates the associated chamber with a green light but changes to a flashing red light if the door is not opened within a preset time. A switch engaged with the door deactivates the LED when the door is opened. The electronic device communicates with the pill box and alerts the patient when it is time to take medication. A remote server can be programmed to control the reminder schedule and monitor the patient's compliance with a prescribed medication regimen.
Patients diagnosed with Borderline Personality disorder and BPDSI score is \> or = 17 will be assigned for active tDCS session (NeuroConn, Germany) candidates will have 20-minute session per day for 10 weekdays in 2 weeks. Then they will attend short term psychotherapy session for 3 months.
FIELD: veterinary microbiology, biotechnology. SUBSTANCE: epizootic culture of necrobacteriosis pathogen is used for vaccine preparing. Culture is grown, inactivated and separated from cultural fluid. Antigenic substances were extracted from biomass and cultural fluid using methods protecting antigen activity at extraction. For antigen extraction from microbial cells biomass is resuspended in distilled water preparing the suspension at concentration 150-250 billion cells/ml. Antigen is extracted from suspension by successive triple freezing-thawing out and their homogenization. Homogenate is centrifuged at 15000-20000g, and protective antigen is isolated from supernatant. The latter is cytoplasmatic fraction containing endotoxin. Simultaneously, exotoxin is isolated from cultural fluid by its precipitation with gelatin at concentration 0.03-0.06 wt.-% Antigens were combined with oily-lanolin adjuvant at the ratio 1:1. EFFECT: improved method of vaccine preparing. 1 tbl
Disclosed are a method for purifying a GLP-1 analog and the use thereof. The purification method comprises: performing reversed-phase purification on a crude peptide solution, performing desalination using a mixed solution of water and an organic solvent as a mobile phase to obtain a refined peptide solution of GLP-1 analog, adjusting the pH to 3.5-5.5, and precipitating at -20°C to 25°C. In the purification method, after reversed-phase purification, desalination and pH adjustment are performed rather than vacuum concentration or membrane concentration, and then precipitation is directly performed without rotary evaporation being required. On one hand, production costs and energy consumption are reduced, thereby improving the efficiency. On the other hand, the obtained purified product is a solid with good stability, can be stored for a long time, is not easily degradable, and is convenient to transfer. In addition, the purification process is simple and efficient, and the precipitation rate is high, which is conducive to large-scale production.
BACKGROUND: The best method of inguinal hernia repair in children continues to be a topic of debate. Although recent data shows that LPEC is superior and safe but no such data exists in our country. Operative time and recurrence are main concerns. Hence, present study is carried out to compare outcome of LPEC versus OHR in children.

OBJECTIVE: To compare the outcome of laparoscopic percutaneous extra-peritoneal closure and open repair for inguinal hernia in children METHODOLOGY: It was a randomized control trial conducted on 66 patients (33 in each group) presented to our hospital with features of Inguinal Hernia. Patients were admitted after confirmation of diagnosis by ultrasound and complete blood count (CBC) was sent. Pre operatively patients were divided in two groups randomly (Open Hernia Repair group, LPEC group) by closed envelope method. Consent was taken from parents regarding inclusion in the study. All demographic data and results were noted down in a proforma. The collected data was entered and analyzed in computer software SPSS (Statistical Package for Social Sciences) version 26.0.
PURPOSE:A quick drying depilatory agent, obtained by filling respective specific amounts of a resin, plasticizer, low-boiling solvent and liquefied gas as a propellant as essential components in an aerosol container and having little pain in depilation, irritancy to the skin and side effect. CONSTITUTION:An aerosol depilatory agent obtained by filling 5-30pts. resin, e.g. butyral resin, 0.1-10pts. nonionic surfactant, preferably sorbitan ester of a fatty acid, 5-60pts. low-boiling solvent, e.g. trichloromonofluoromethane, and 20-75pts. liquefied gas, e.g. dichlorodifluoromethane, as a propellant and as necessary an adequate amount of a pigment or dye added thereto to give 100pts. total amount in an aerosol container and mounting a valve for the aerosol and button on the container. The above-mentioned depilatory agent has much less pain in depilation, better operability and less irritancy to the skin than the conventional type of depilatory agent and further quick drying properties. Therefore, the depilation can be carried out over a wide range in a short time.
PROBLEM TO BE SOLVED: To produce a pyroligneous acid whose smoking smell or phenol smell is reduced, to provide a method for producing the same, and to provide a food, perfumery or household article containing the pyroligneous acid. SOLUTION: The pyroligneous acid whose smoking smell or phenol smell is reduced is obtained by bringing the pyroligneous acid into contact with a porous polymer resin or silica gel. The method for producing the pyroligneous acid is provided. Further, the food, perfumery or household article containing the pyroligneous acid is provided. In the pyroligneous acid, the smoking smell or phenol smell of conventional pyroligneous acid, liable to be aversive by a part of persons is largely reduced. Thereby, the uses of the pyroligneous acid are further spread, and the palatability of a food, a perfumery, a household article, or the like, containing the pyroligneous acid is further enhanced.
Letrozole combined with acupuncture and Du Meridian moxibustion was taken from 3-5 days of menstrual period (spontaneous menstruation or progesterone withdrawal bleeding). The acupuncture treatment was 3 times / week, with an interval of 2-4 days, 12 times a week, 30 minutes each time; Du Meridian moxibustion is 20 minutes each time, once a week, four times a week. The initial dose of letrozole was 2.5mg/day for 5 consecutive days. The follow-up dose was determined according to the response of the subjects to the initial dose, with one month as a cycle. If not pregnant, the subjects received letrozole for up to 4 cycles to induce ovulation with acupuncture plus Du Meridian moxibustion.
Patients with CV-19 and not in the acute period. This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).
PROBLEM TO BE SOLVED: To prepare a fine powder medicine of a fat emulsion, liposome or a micro lipid sphere, etc., excellent in preservation stability by reducing the elusion of iron from a homogenizer and high pressure emulsifier. SOLUTION: The content of iron in a fine powder medicine is reduced to <=100ppb. The content of the iron can be reduced by removing an oxidative membrane at the wetted part by washing various emulsifiers at a high speed and under a high pressure before emulsifying process. The preferable content of the iron is <=50ppb. The included iron has the form of a divalent or trivalent iron ion, these iron oxide and an iron powder. The fine powder medicine is also used as a freeze dried medicine.
Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 140ml a day for 2 weeks, and finally visit the investigators once more following another 140ml drink.
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
BACKGROUND Although recurrence after surgery for esophagogastric junction (EGJ) adenocarcinoma frequently develops in the mediastinal and para-aortic lymph nodes (LN), distant LN recurrence in the mesocolon is rare. We report a rare case of ileocecal LN metastasis in the ascending mesocolon after radical surgery for an EGJ adenocarcinoma. CASE REPORT We performed subtotal esophagectomy with mediastinal and para-gastric LN dissection in a patient with an advanced EGJ adenocarcinoma. Clinicopathologically, the patient was diagnosed with type I EGJ adenocarcinoma based on Siewert's classification (pathological T3N1M0). One year after surgery, computed tomography showed enlarged lymph nodes around the ileocolic artery, and further examination was performed. Although positron emission tomography-computed tomography showed that the lesion had moderate uptake of fluorodeoxyglucose, we did not find the reason for the enlarged lymph nodes. Finally, laparoscopic ileocecal resection was performed for diagnostic and therapeutic purposes. Clinicopathological tests revealed that the specimen was a moderately differentiated adenocarcinoma, which was strongly suspected to be a metastasis of the EGJ adenocarcinoma. CONCLUSIONS We encountered a rare case of EGJ adenocarcinoma that spread to the ileocecal LN in the ascending mesocolon. To the best of our knowledge, this is the first such report in the literature to date. Laparoscopic ileocecal resection for metastasis to the ascending mesocolon seems reasonable as a local control.
The intervention arm is 3 months closed loop control of blood glucose with the BIHAP. The BIHAP contains a self-learning algorithm which automatically maintains the glucose levels within target limits via subcutaneous administration of insulin (Humalog®) and glucagon. Patients complete a training period before the intervention period will start.
The airway clearance regimen for subjects in the control group will be collected from the medical record.This information will be retrospectively collected from patients treated with standard care with no OLE therapy. Subjects in the control group will be identified from the population of patients previously admitted to the two study sites with COVID-19 infection who required invasive mechanical ventilation but were not treated with OLE therapy.
Pancreatic cancer is a very aggressive and fatal malignancy with few therapeutic choices and a poor prognosis. Understanding the molecular pathways that drive its growth is critical for developing effective therapeutic strategies. Exosomes, small extracellular vesicles secreted by numerous cell types, have recently emerged as essential intercellular communication mediators, with implications for tumor growth and metastasis. In this article, we present a review of current knowledge about exosomes and their role in pancreatic cancer progression We discuss the biogenesis and characteristics of exosomes, as well as their cargo and functional significance in tumor growth, immune evasion, angiogenesis, invasion, and metastasis. We further emphasize the potential of exosomes as diagnostic biomarkers and therapeutic targets for pancreatic cancer. Finally, we discuss the challenges and future perspectives in using exosomes to improve patient outcomes in pancreatic cancer.
The following adverse events have been identified during post-approval use of terbinafine hydrochloride. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. 

Adverse events, based on worldwide experience with terbinafine tablets use, include: idiosyncratic and symptomatic hepatic injury and more rarely, cases of liver failure, some leading to death or liver transplant, serious skin reactions (e.g., Stevens-Johnson Syndrome and toxic epidermal necrolysis), severe neutropenia, thrombocytopenia, agranulocytosis, pancytopenia, anemia, angioedema, and allergic reactions (including anaphylaxis) [see Warnings and Precautions (5.1, 5.5 , and 5.6)]. 

Psoriasiform eruptions or exacerbation of psoriasis, acute generalized exanthematous pustulosis and precipitation and exacerbation of cutaneous and systemic lupus erythematosus have been reported in patients taking terbinafine hydrochloride [see Warnings and Precautions (5.7)]. 

Cases of taste disturbance, including taste loss, have been reported with the use of terbinafine tablets. It can be severe enough to result in decreased food intake, weight loss, and depressive symptoms [see Warnings and Precautions (5.2)]. Depressive symptoms independent of taste disturbance have been reported with use of terbinafine tablets. In some cases, depressive symptoms have been reported to subside with discontinuance of therapy and to recur with reinstitution of therapy [see Warnings and Precautions (5.4)]. Cases of smell disturbance, including smell loss, have been reported with the use of terbinafine tablets [see Warnings and Precautions (5.3)]. 

Other adverse reactions which have been reported include malaise, fatigue, vomiting, arthralgia, myalgia, rhabdomyolysis, reduced visual acuity, visual field defect, hair loss, serum sickness-like reaction, vasculitis, pancreatitis, influenza-like illness, pyrexia, increased blood creatine phosphokinase, photosensitivity reactions, tinnitus, hearing impairment and vertigo.

Altered prothrombin time (prolongation and reduction) in patients concomitantly treated with warfarin has been reported.
INTRODUCTION: Postpartum depression (PPD) is a growing mental health concern worldwide and has detrimental effects on the social and cognitive health of both mothers and infants. This review was performed to assess the risk of PPD in women with postpartum hemorrhage (PPH) and to identify potential moderators.
MATERIAL AND METHODS: The review protocol was registered in the PROSPERO database on June 17, 2023 (registration number: CRD42023432955). Two researchers independently performed a literature search of the PubMed, Embase, and Web of Science databases for articles published before May 25, 2023, with no filters and no language or location restrictions. Study quality was evaluated using the Newcastle-Ottawa Scale. The primary outcome was the odds ratio (OR) and 95% confidence interval (CI) of PPD in women with vs. without PPH. We performed sensitivity analyses and meta-regression analyses to resolve heterogeneity. Meta-regression analyses included the effects of age, maternal smoking, marital status, preterm labor, maternal education level, preeclampsia, anemia during pregnancy, and cesarean section.
RESULTS: In total, seven studies involving 540 558 participants met the eligibility criteria and were included in the meta-analysis. Women with PPH were at increased risk of PPD compared with women without PPH (OR 1.10; 95% CI 1.03-1.16), and heterogeneity was low (I2 = 23%; τ2 = 0.0007; p = 0.25). Moreover, the results of the sensitivity analyses showed that the I2 value decreased from 23% to 0% after excluding one particular study, which may have been a source of heterogeneity. In the meta-regression analyses, the OR of PPD was greatly affected by maternal smoking (OR -0.26; 95% CI -0.30 to -0.22; p < 0.001). However, we did not observe any effects for maternal age, marital status, preterm labor, maternal education level, preeclampsia, anemia during pregnancy, or cesarean section.
CONCLUSIONS: Women with PPH must be closely monitored because they have a higher risk of PPD than women without PPH. Early recognition and management of these patients will improve treatment outcomes, maternal health, and newborn development.
Each 5 mL (one teaspoonful), for oral administration contains: Promethazine hydrochloride 6.25 mg; phenylephrine hydrochloride 5 mg. Alcohol 7%.

Inactive Ingredients: Apricot peach flavor, ascorbic acid, citric acid, FD&C yellow #6, menthol, methylparaben, propylene glycol, propylparaben, purified water, saccharin sodium, sodium benzoate, sodium citrate and sucrose.

Promethazine hydrochloride, a phenothiazine derivative, is chemically designated as (±)-10-[2-(Dimethylamino)propyl] phenothiazine monohydrochloride.

Promethazine hydrochloride occurs as a white to faint yellow, practically odorless, crystalline powder which slowly oxidizes and turns blue on prolonged exposure to air. It is soluble in water and freely soluble in alcohol. It has a molecular weight of 320.88, a molecular formula of C17H20N2S•HCI, and the following structural formula:

Phenylephrine hydrochloride is a sympathomimetic amine salt which is chemically designated as (-)-m-Hydroxy-α-[(methylamino)methyl] benzyl alcohol hydrochloride. It occurs as white or nearly white crystals, having a bitter taste. It is freely soluble in water and alcohol. Phenylephrine hydrochloride is subject to oxidation and must be protected from light and air. It has a molecular weight of 203.67, a molecular formula of C9H13NO2•HCI, and the following structural formula:
PURPOSE: Phenylalkylcarboxylic acid derivatives are useful as a remedy or preventive for hyperglycemia and the like without depending on insulin and pharmacologically acceptable salts and esters thereof are provided. CONSTITUTION: The phenylalkylcarboxylic acid derivatives are represented by formula (I) and pharmacologically acceptable salts and esters thereof. In the formula, R1 represents alkyl, etc.; R2 represents alkylene; R3 represents hydrogen, etc.; X represents (un)substituted aryl, etc.; Y represents oxygen, etc.; Z represents alkylene, etc.; and W represents alkyl, etc. The compound is characterized by having an oxime bond in the side chain.
PURPOSE:To issue the previous prescription equally to some extent, or in a set ratio at every medical examination department even if patients of plural medical examination departments are not received equally by issuing the previous prescription of plural medical examination departments by a prescribed number of persons from a printer. CONSTITUTION:First of all, a second point is set to '1', and a receiving file to be read out is set to a receiving file 5A of the internal department. Also, the number of persons issued already is reset to '0'. Thereafter, whether new receiving data which is not read out exists in the receiving file 5A of the internal department or not is decided, and in the case it exists, its receiving data is read out. Subsequently, by referring to a patient code in the receiving data, the previous prescription information of a patient is read out of a patient data file 4, sent out to a printer 7 from a terminal machine 8, and by this printer 7, the previous prescription is issued. Next, with respect to a changed receiving file 5B of the surgical department, as well, the entirely same processing is executed, and issue of the previous prescription is executed.
PURPOSE: A composition containing Erigeron annuus (L.) Pers. as an active ingredient for preventing and treating diabetes is provided to suppress generation of advanced glycation end products and abnormal activation of aldose reductase. CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes complication contains Erigeron annuus (L.) Pers. extract or its fraction of ethylacetate layer or normal buthanol layer. The Erigeron annuus (L.) Pers. extract is obtained from flower, root or stem of the Erigeron annuus (L.) Pers. with alcohol.